Advertise on podcast: BioTech IQ

Cell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is where the biotech company, Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases. Ammon and Spiro go over the use of Cyclin-dependent Kinase and its role in the cell cycle. Spiro also talks about Cyclacel's pipeline and drug candidates. They also go through discussion strategy, the drug approval process, and what it means to fail fast.

Have you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and where they’re going from there.

The biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits down with two-peat guest, Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Guillermo also shares his experience learning and re-learning the science in both languages and how it impacts communication. Don’t miss out on their enlightening conversation by tuning in!

In this episode of BioTech IQ host Ammon Rivera talks about the current state of the market with respect to recruiting. He also shares a real and recent experience highlighting the challenges of compensation and it role in landing the right individual for the job.  https://thebiotechiqpodcast.com/ https://www.linkedin.com/in/ammonr/

On this episode of BioTech IQ, Ammon Rivera interviews Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of those, about a fifth will likely develop NASH. It’s a big problem that affects a lot of people. The company’s lead drug candidate, Rencofilstat, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Tune in to learn more about their pharmaceutical development process and other possibilities with the drug in terms of treatment.

Some of the main problems with sequencing in identifying mutations are its cost and the time it takes. Fortunately, with the rapid growth of technology, revolutionary products that simplify processes are being made. One of those is from DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background noise" in testing, allowing for the detection of the "bad actor." Join in to learn the processes behind their work, what this means to the future of testing and treating diseases, and where the company is headed. Don't miss out!

In this episode of BioTech IQ Ammon interviews professional coach Jeff Harmon. Jeff specializes in working with life science companies by helping them develop their unique company cultures that drives success at all levels.

TNF is a protein that contributes to inflammation. Anti-TNFs can be used to stabilize this and stop the inflammation. It's used for diseases like arthritis and psoriasis. Discover how clinical trials are done so these medicines and anti-TNFs can be utilized. Join Ammon Rivera as he talks to M.D., Ph.D. and CEO of 180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim's goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim's career as a venture capitalist. Find out why trials need to be uniform and randomized. And, discover what it takes to run a biotech company today.

This episode of BioTech IQ features James Mackay, PhD, Founder and CEO of Aristea Therapeutics. Aristea Therapeutics is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases. In particular, their lead asset is addressing palmoplantar pustulosis (PPP), a rare, chronic inflammatory skin condition with no approved therapy in the United States that affects about 100,000 people. Don't miss this episode as we discuss James' background and the strategy of Aristea's approach to their current asset. https://aristeatx.com/ Check out out more episodes at https://thebiotechiqpodcast.com/

This episode on BioTech IQ is actually a recording of two separate interviews. In the first half of the show I interview Pete Mariani who is the CFO of Axogen, Inc. Pete has strong experience in public markets experience including successful raises of equity, debt and strategic financing; driving strong, consistent investor communication and strategies; and establishing solid SEC reporting structures.  The second guest is Robert w. Mays, Ph.D, Co-Founder and Vice President of Regenerative Medicine and Neuroscience programs at Athersys, Inc.  Dr. Mays has more than 25 years of experience in technology development, drug discovery and translational stem cell experience. https://thebiotechiqpodcast.com/

On this episode of BioTech IQ Ammon interviews Maria Maccechini is an accomplished scientist, successful biotech executive, and angel investor. She is the CEO of Annovis Bio, Attacking Alzheimer's Disease and Neurodegeneration by Improving AXONAL TRANSPORT , this enhances the FLOW of Information Along the Information Highway of Nerve Cells. https://www.annovisbio.com/ https://thebiotechiqpodcast.com/

James Joyce is the CEO, Chairman of the board, and a co-founder at Sigyn Therapeutics. Did you know that multiple healthcare agencies report "community acquired pneumonia" as the number cause of infectious disease death? And this indication leads to about 50% of sepsis cases? On this episode of BioTech IQ we discuss Sigyn Therapeutics blood purification device can calm the storm and change that.  https://www.sigyntherapeutics.com/ https://thebiotechiqpodcast.com/ https://www.linkedin.com/in/ammonr/